These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12911841)

  • 1. Peroxisome proliferator activated receptors and stroke.
    Fruchart JC; Bordet R; Duriez P
    Curr Atheroscler Rep; 2003 Sep; 5(5):331-2. PubMed ID: 12911841
    [No Abstract]   [Full Text] [Related]  

  • 2. PPARalpha ligands and clinical trials: cardiovascular risk reduction with fibrates.
    Robins SJ
    J Cardiovasc Risk; 2001 Aug; 8(4):195-201. PubMed ID: 11550997
    [No Abstract]   [Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Broeders N; Abramowicz D
    Kidney Int; 2002 Jan; 61(1):354-5. PubMed ID: 11786122
    [No Abstract]   [Full Text] [Related]  

  • 4. Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors.
    Wahli W; Devchand PR; IJpenberg A; Desvergne B
    Adv Exp Med Biol; 1999; 447():199-209. PubMed ID: 10086196
    [No Abstract]   [Full Text] [Related]  

  • 5. PPAR-alpha: a key to the mechanism of hepatoprotection by clofibrate.
    Mehendale HM
    Toxicol Sci; 2000 Oct; 57(2):187-90. PubMed ID: 11006348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha.
    Shoji Y; Sanekata A; Sato M; Imaizumi K
    Biosci Biotechnol Biochem; 2003 May; 67(5):1177-8. PubMed ID: 12834305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fenofibrate].
    Yamashita T; Nakamura H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
    [No Abstract]   [Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.
    Fruchart JC
    Am J Cardiol; 2001 Dec; 88(12A):24N-29N. PubMed ID: 11788127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators.
    Hertz R; Sheena V; Kalderon B; Berman I; Bar-Tana J
    Biochem Pharmacol; 2001 May; 61(9):1057-62. PubMed ID: 11301038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.
    Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Trends Pharmacol Sci; 2003 Oct; 24(10):530-4. PubMed ID: 14559405
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration.
    Rodríguez C; Noé V; Cabrero A; Ciudad CJ; Laguna JC
    Mol Pharmacol; 2000 Jul; 58(1):185-93. PubMed ID: 10860941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
    Grommes C; Landreth GE; Heneka MT
    Lancet Oncol; 2004 Jul; 5(7):419-29. PubMed ID: 15231248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear receptors as potential targets for modulating reverse cholesterol transport.
    Pelton PD; Patel M; Demarest KT
    Curr Top Med Chem; 2005; 5(3):265-82. PubMed ID: 15857310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.
    Forman BM; Chen J; Evans RM
    Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4312-7. PubMed ID: 9113986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Guan Y; Breyer MD
    Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice.
    Inoue H; Jiang XF; Katayama T; Osada S; Umesono K; Namura S
    Neurosci Lett; 2003 Dec; 352(3):203-6. PubMed ID: 14625020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats.
    Moya-Camarena SY; Van den Heuvel JP; Belury MA
    Biochim Biophys Acta; 1999 Jan; 1436(3):331-42. PubMed ID: 9989264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
    Beckman J; Raji A; Plutzky J
    Curr Opin Cardiol; 2003 Nov; 18(6):479-85. PubMed ID: 14597889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).
    Sporn MB; Suh N; Mangelsdorf DJ
    Trends Mol Med; 2001 Sep; 7(9):395-400. PubMed ID: 11530334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.
    Krey G; Braissant O; L'Horset F; Kalkhoven E; Perroud M; Parker MG; Wahli W
    Mol Endocrinol; 1997 Jun; 11(6):779-91. PubMed ID: 9171241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.